Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. The company offers Actimab-A, a CD33 targeting radiotherapeutic for patients with Relapsed/Refractory AML...
27 insider purchases on record · latest filing 2018-12-10.
Insiders have also filed 120 sale transactions at ATNM.